Richard Page

Partner

Ph.D., M.Sc., B.Sc.

Dr. Page is authorized to represent clients before the European Patent Office. He has been active in intellectual property law since 2012 and complements our Biotechnology and Pharmaceuticals Division as European Patent Attorney.
+ 49 89 210 296 0
richard.page@df-mp.com

 

 

Richard Page

Partner

Ph.D., M.Sc., B.Sc.

Dr. Page is authorized to represent clients before the European Patent Office. He has been active in intellectual property law since 2012 and complements our Biotechnology and Pharmaceuticals Division as European Patent Attorney.
+ 49 89 210 296 0
richard.page@df-mp.com

 

 

practice areas.

Richard Page's scientific background lies in protein biochemistry, molecular biology, cell biology and neuroscience. Dr. Page is involved in patent drafting and prosecution concerning European patents. He is also active in opposition and appeal matters before the European Patent Office.

 

Two Rising IP Stars for df-mp
Two Rising IP Stars for df-mp

df-mp is hono­red with two new stars: Audrey Nickel and…

admissions.

  • European Patent Attorney

references and activities.

  • Author of scientific publications

curriculum vitae.

Since 2023
Since 2023

Part­ner at df-mp

2022-2023
2022-2023

Asso­cia­te Direc­tor IP in a glo­bal bio­tech­no­lo­gy com­pa­ny

2017-2022
2017-2022

Patent Att­or­ney at df-mp

2012-2017
2012-2017

Patent Att­or­ney Trai­nee at df-mp

2009-2012
2009-2012

Seni­or Post­doc­to­ral Sci­en­tist, Ger­man Cent­re for Neu­ro­de­ge­nera­ti­ve Dise­a­ses (DZNE), Lud­wig Maxi­mi­li­ans Uni­ver­si­ty, Munich, Ger­ma­ny

2006-2009
2006-2009

Post­doc­to­ral Sci­en­tist, Depart­ment of Bio­che­mis­try, Lud­wig Maxi­mi­li­ans Uni­ver­si­ty, Munich, Ger­ma­ny

2003-2006
2003-2006

Ph.D. in Bio­che­mis­try, Cam­bridge Insti­tu­te for Medi­cal Rese­arch, Uni­ver­si­ty of Cam­bridge, UK (spon­so­red by Merck & Co.). Win­ner of the West­mins­ter Medal at the 2006 ‘SET for Bri­tain’ com­pe­ti­ti­on

2002-2003
2002-2003

M.Sc. in Neu­ro­sci­ence (with Distinc­tion), Insti­tu­te of Psych­ia­try, King’s Col­lege, Uni­ver­si­ty of Lon­don, UK

1998-2001
1998-2001

B.Sc. in Bio­che­mis­try (2:1 with Hono­urs), Impe­ri­al Col­lege, Uni­ver­si­ty of Lon­don, UK

publications.

  • Page RM, Münch A, Horn T, Kuhn PH, Colombo A, Reiner O, Boutros M, Steiner H, Lichtenthaler SF, Haass C. Loss of PAFAH1B2 reduces amyloid-β generation by promoting the degradation of amyloid precursor protein C-terminal fragments. J Neurosci. 2012, 32 (50):18204-14.
  • Mitterreiter S, Page RM, Kamp F, Hopson J, Winkler E, Ha H-R, Hamid R, Herms J, Mayer TU, Nelson DJ, Steiner H, Stahl T, Zeitschel U, Rossner S, Haass C, Lichtenthaler SF. Bepridil and amiodarone simultaneously target the Alzheimer's disease β- and γ-secretase by distinct mechanisms. J Neurosci. 2010, 30(26): 8974-83.
  • Page RM, Gutsmiedl A, Fukumori A, Winkler E, Haass C and Steiner H. APP mutants respond to γ-secretase modulators. J Biol Chem.2010 285(23): 17798-810.
  • Fuhrmann M, Bittner T, Jung CKE, Burgold S, Page RM, Mitteregger G, Haass C, LaFerla FM, Kretzschmar H and Herms J. Microglia CX3CR1 knockout prevents neuron loss in an Alzheimer's disease mouse model. Nat Neurosci. 2010 13(4): 411-3.
  • Rival T*, Page RM*, Chandraratna D, Sendall T, Lewis H, Ryder E, Rosahl T, Camargo LM, Shearman MS, Crowther DC and Lomas DA. Fenton chemistry and oxidative stress mediate the toxicity of the Aβ peptide in vivo. Eur J Neurosci.2009, (29)7: 1335-47. *joint first author
  • Page RM, Baumann K, Tomioka M, Pérez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H and Haass C. Generation of Aβ38 and Aβ42 is independently and differentially affected by FAD-associated presenilin 1 mutations and γ-secretase modulation. J Biol Chem. 2008, 283(2): 677-83.
  • Crowther DC, Page R, Chandraratna D and Lomas DA. A Drosophila model of Alzheimer's disease. Methods in Enzymology. 2006, 412: 234-55.
  • Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, Gubb DC and Lomas DA. Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease.Neuroscience. 2005, 132: 123-135.
  • Lomas DA, Belorgey D, Mallya M, Onda M, Kinghorn KJ, Sharp LK, Phillips RL, Page R, Crowther DC, Miranda E. Polymerisation underlies α1-antitrypsin deficiency, dementia and other serpinopathies. Front Biosci. 2004, 1;9: 2873-91.